| Literature DB >> 27189120 |
Philip T Cherian1, Aditi Deshpande2, Martin N Cheramie1, David F Bruhn1, Julian G Hurdle2,3, Richard E Lee1.
Abstract
Exploiting iron-uptake pathways by conjugating β-lactam antibiotics with iron-chelators, such as catechol and hydroxamic acid is a proven strategy to overcome permeability-related resistance in Gram-negative bacteria. As naturally occurring iron-chelating tetramic acids have not been previously examined for this purpose, an exploratory series of novel ampicillin-tetramic acid hybrids that structurally resemble ureidopenicillins was designed and synthesized. The new analogs were evaluated for the ability to chelate iron and their MIC activities determined against a representative panel of clinically significant bacterial pathogens. The tetramic acid β-lactam hybrids demonstrated a high affinity to iron in the order of 10-30 M3. The hybrids were less active against Gram-positive bacteria. However, against Gram-negative bacteria, their activity was species dependent with several hybrids displaying improved activity over ampicillin against wild-type Pseudomonas aeruginosa. The anti-Gram-negative activities of the hybrids improved in the presence of clavulanic acid revealing that the tetramic acid moiety did not provide added protection against β-lactamases. In addition, the hybrids were found to be efflux pump substrates as their activities markedly improved against pump-inactivated strains. Unlike the catechol and hydroxamic acid siderophore β-lactam conjugates, the activities of the hybrids did not improve under iron-deficient conditions. These results suggest that the tetramic acid hybrids gain permeability via different membrane receptors, or they are outcompeted by native bacterial siderophores with stronger affinities for iron. This study provides a foundation for the further exploitation of the tetramic acid moiety to achieve novel β-lactam anti-Gram-negative agents, providing that efflux and β-lactamase mediated resistance is addressed.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27189120 PMCID: PMC5116011 DOI: 10.1038/ja.2016.52
Source DB: PubMed Journal: J Antibiot (Tokyo) ISSN: 0021-8820 Impact factor: 2.649
Figure 1A. Structures of catecholate-based siderophore-ampicillin conjugates. B. Design of ampicillin - tetramic acid hybrids inspired by piperacillin and carbenicillin.
Figure 2Structures of ampicillin – tetramic acid hybrids
Scheme 1Synthesis of ampicillin – tetramic acid hybrids. Reagents and conditions: a)TEA/DCM b)NaOMe/MeOH c)ampicillin/DMF/MW/100°C/3mins
Figure 3Tautomerism of 3-carbonyl tetramic acids
MIC (µg/ml) of ampicillin-tetramic acid hybrids against gram-positive bacteria.
| Compound | EF | SPy | SP | BA | BS | MSSA | MRSA |
|---|---|---|---|---|---|---|---|
| ampicillin | 3.13 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | 50 |
| piperacillin | 3.13 | <0.2 | <0.2 | 0.39 | 0.39 | <0.2 | 25 |
| carbenicillin | 3.13 | <0.2 | <0.2 | <0.2 | <0.2 | <0.2 | 6.25 |
| 1903 | 25 | 0.39 | 0.39 | 3.13 | 1.56 | 0.78 | 25 |
| 1905 | 50 | 0.78 | <0.2 | 3.13 | 3.13 | 0.78 | 50 |
| 1940 | 25 | 0.78 | 0.78 | 3.13 | 3.13 | 1.56 | 25 |
| 2742 | 25 | 1.56 | 1.56 | 6.25 | 3.13 | 1.56 | 100 |
| 2743 | 12.5 | <0.2 | <0.2 | 0.78 | 0.78 | 0.78 | 25 |
| 2744 | 12.5 | 0.78 | 0.39 | 6.25 | 3.13 | 1.56 | 25 |
| 2745 | 12.5 | 0.78 | 0.39 | 6.25 | 3.13 | 0.78 | 25 |
| 2746 | 25 | 0.39 | 0.39 | 1.56 | 3.13 | 1.56 | 50 |
| 2780 | 25 | 0.78 | 0.39 | 1.56 | 0.78 | 0.39 | 50 |
| 2781 | 25 | 0.39 | <0.2 | 3.13 | 0.78 | <0.2 | 25 |
| 2782 | 6.25 | 0.78 | 0.39 | 3.13 | 1.56 | 0.39 | 12.5 |
| 2833 | 12.5 | 0.78 | <0.2 | 1.56 | 0.39 | <0.2 | 25 |
| 2835 | 25 | 0.78 | <0.2 | 3.13 | <0.2 | <0.2 | 25 |
| 2916 | 25 | 0.39 | <0.2 | 1.56 | 1.56 | <0.2 | 50 |
| 2917 | 25 | 0.39 | <0.2 | 3.13 | 1.56 | 0.78 | 50 |
| 2918 | 25 | 1.56 | 0.39 | 6.25 | 3.13 | 0.78 | 50 |
| 2919 | 25 | 0.78 | <0.2 | 3.13 | 1.56 | 0.78 | 50 |
| 3002 | 25 | 0.39 | 0.39 | 3.13 | 1.56 | 0.78 | 50 |
Key: EF= E. faecalis ATCC33186; SPy= S. pyogenes ATCC700294; SP= S. pneumoniae R6; BA= B. anthracis sterne; BS= B. subtilis ATCC23857; MSSA= S. aureus -ATCC29213; MRSA= S. aureus NRS 70.
MIC (µg/ml) of ampicillin-tetramic acid hybrids against gram-negative bacteria.
| Compound | AB | EC | EC | PV | PM | KP | PA |
|---|---|---|---|---|---|---|---|
| ampicillin | 100 | 3.13 | 3.13 | 100 | 3.13 | 100 | >200 |
| piperacillin | 6.25 | 6.25 | 1.56 | 1.56 | 0.19 | 6.25 | 6.25 |
| carbenicillin | 100 | 100 | 0.09 | 100 | 1.56 | 50 | 100 |
| 1903 | 50 | 50 | 6.25 | 25 | 12.5 | 200 | 12.5 |
| 1905 | 200 | 25 | 6.25 | 50 | 25 | 200 | 25 |
| 1940 | 100 | 50 | 12.5 | 50 | 6.25 | >200 | 25 |
| 2742 | 100 | 100 | 12.5 | 100 | 6.25 | >200 | 25 |
| 2743 | 50 | 200 | 12.5 | 100 | 3.13 | >200 | 25 |
| 2744 | 100 | 100 | 3.13 | 12.5 | 12.5 | >200 | 25 |
| 2745 | 50 | 100 | 3.13 | 12.5 | 3.13 | >200 | 25 |
| 2746 | 200 | 200 | 12.5 | 100 | 3.13 | >200 | 50 |
| 2780 | >200 | 200 | 6.25 | 12.5 | 1.56 | >200 | 25 |
| 2781 | 50 | 100 | 3.13 | 6.25 | 3.13 | >200 | 12.5 |
| 2782 | 25 | 25 | 1.56 | 12.5 | 12.5 | >200 | 25 |
| 2833 | 25 | 100 | 3.13 | 100 | 6.25 | 200 | 25 |
| 2835 | 50 | 100 | 3.13 | 25 | 25 | 200 | 25 |
| 2916 | 50 | 50 | 1.56 | 6.25 | 6.25 | >200 | 25 |
| 2917 | 50 | 12.5 | 6.25 | 6.25 | 3.1 | >200 | 25 |
| 2918 | 100 | 6.25 | 6.25 | 6.25 | 6.25 | >200 | 50 |
| 2919 | 25 | 12.5 | 3.13 | 25 | 50 | 200 | 50 |
| 3002 | 50 | 6.25 | 3.13 | 25 | 1.56 | 200 | 12.5 |
Key: AB= A. baumannii ATCC 19606; EC= E. coli BW25113; ECΔtolC= E. coli BW25113 ΔtolC derivative JW5503-1; PV= P. vulgaris ATCC 33420; PM= P. mirabilis ATCC 25933; KP= K. pneumoniae ATCC 13883; PA= P. aeruginosa PA01.
MIC (µg/ml) of ampicillin-tetramic acid hybrids against gram-negative bacteria in presence of clavulanic acid.
| Compounds | EC | KP | ECΔ | PA | ||||
|---|---|---|---|---|---|---|---|---|
| + | − | + | − | + | − | + | − | |
| ampicillin | 1.56 | 3.13 | 25 | 100 | 1.56 | 3.13 | 100 | >200 |
| piperacillin | 3.13 | 6.25 | 6.25 | 6.25 | 1.56 | 1.56 | 3.13 | 6.25 |
| 1903 | 12.5 | 50 | 25 | 200 | 1.56 | 6.25 | 6.25 | 12.5 |
| 1905 | 12.5 | 25 | 100 | 200 | 12.5 | 25 | 12.5 | 25 |
| 1940 | 12.5 | 50 | 25 | >200 | 6.25 | 12.5 | 12.5 | 25 |
| 2742 | 25 | 100 | 100 | >200 | 12.5 | 25 | 12.5 | 25 |
| 2743 | 12.5 | 200 | 25 | >200 | 6.25 | 12.5 | 12.5 | 25 |
| 2744 | 25 | 100 | 25 | >200 | 12.5 | 25 | 25 | 25 |
| 2745 | 12.5 | 100 | 25 | >200 | 6.25 | 6.25 | 25 | 25 |
| 2746 | 50 | 200 | >200 | >200 | 25 | 50 | 25 | 50 |
| 2780 | 50 | 200 | 25 | >200 | 3.13 | 12.5 | 12.5 | 25 |
| 2781 | 6.25 | 100 | 50 | >200 | 3.13 | 6.25 | 3.13 | 12.5 |
| 2782 | 3.13 | 25 | 50 | >200 | 3.13 | 6.25 | 12.5 | 25 |
| 2833 | 12.5 | 100 | 100 | 200 | 6.25 | 12.5 | 6.25 | 25 |
| 2835 | 6.25 | 100 | 100 | 200 | 12.5 | 50 | 6.25 | 25 |
| 2916 | 12.5 | 50 | 100 | >200 | 3.13 | 6.25 | 6.25 | 25 |
| 2917 | 12.5 | 12.5 | 50 | >200 | 12.5 | 25 | 6.25 | 25 |
| 2918 | 12.5 | 6.25 | 50 | >200 | 6.25 | 25 | 6.25 | 50 |
| 2919 | 50 | 12.5 | 100 | 200 | 6.25 | 12.5 | 12.5 | 50 |
| 3002 | 6.25 | 6.25 | 25 | 200 | 6.25 | 6.25 | 3.13 | 12.5 |
Key: EC= E. coli BW25113; KP= K. pneumoniae ATCC 13883; PA= P. aeruginosa PA01; ECΔampC – E. coli BW25113 ΔampC derivative JW4111-2. Clavulanic acid MICs were 100 µg/ml against EC and KP; 200 µg/ml against PA; and 25 µg/ml against ECΔampC.
MIC (µg/ml) of ampicillin-tetramic acid hybrids against P. aeruginosa and E. coli in the presence of carbonyl cyanide m-chlorophenyl hydrazone and 2, 2′-bipyridyl.
| PA | EC | ECΔ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MH | MH+CCCP | MH+BP | MH+BP/CCCP | MH | MH+CCCP | MH+BP | MH+BP/CCCP | MH | MH+CCCP | MH+BP | MH+BP/CCCP | |
| Ampicillin | >200 | >200 | >200 | 12.5 | 3.13 | 1.56 | 3.13 | 0.78 | 3.13 | 1.56 | 3.13 | 0.39 |
| Piperacillin | 6.25 | 3.13 | 6.25 | 3.13 | 12.5 | 6.25 | 1.56 | 0.78 | 0.09 | 0.09 | 0.09 | 0.09 |
| Carbenicillin | 200 | 25 | 50 | 1.56 | 6.25 | 12.5 | 6.25 | 0.78 | 1.56 | 0.78 | 0.56 | 0.78 |
| 1903 | 12.5 | 3.13 | 12.5 | 1.56 | 50 | 25 | 50 | 12.5 | 6.2 | 1.56 | 1.56 | 3.13 |
| 1905 | 25 | 3.13 | 6.25 | 0.78 | 25 | 12.5 | 12.5 | 6.25 | 6.25 | 1.56 | 1.56 | 0.78 |
| 1940 | 25 | 12.5 | 12.5 | 6.25 | 50 | 25 | 25 | 12.5 | 12.5 | 6.25 | 3.13 | 1.56 |
| 2742 | 25 | 12.5 | 12.5 | 6.25 | 100 | 50 | 100 | 12.5 | 12.5 | 6.25 | 6.25 | 1.56 |
| 2743 | 25 | 6.25 | 12.5 | 3.13 | 200 | 25 | 50 | 12.5 | 12.5 | 3.13 | 6.25 | 1.56 |
| 2744 | 25 | 12.5 | 50 | 25 | 100 | 25 | 50 | 25 | 3.13 | 1.56 | 3.13 | 0.78 |
| 2745 | 25 | 12.5 | 50 | 12.5 | 100 | 12.5 | 50 | 12.5 | 3.13 | 1.56 | 1.56 | 0.78 |
| 2746 | 50 | 12.5 | 50 | 12.5 | 200 | 12.5 | 100 | 12.5 | 12.5 | 3.13 | 6.25 | 1.56 |
| 2780 | 25 | 6.25 | 25 | 6.25 | 200 | 25 | 50 | 25 | 6.25 | 3.13 | 6.25 | 3.13 |
| 2781 | 12.5 | 3.13 | 6.25 | 1.56 | 100 | 25 | 25 | 3.13 | 3.13 | 1.56 | 3.13 | 1.56 |
| 2782 | 25 | 12.5 | 25 | 12.5 | 25 | 25 | 12.5 | 3.13 | 1.56 | 1.56 | 3.13 | 1.56 |
| 2833 | 25 | 12.5 | 25 | 12.5 | 100 | 50 | 50 | 6.25 | 3.13 | 1.56 | 1.56 | 0.78 |
| 2835 | 25 | 12.5 | 25 | 12.5 | 100 | 25 | 25 | 12.5 | 3.13 | 1.56 | 1.56 | 0.78 |
| 2916 | 25 | 12.5 | 25 | 6.25 | 50 | 25 | 25 | 12.5 | 1.56 | 0.78 | 1.56 | 0.78 |
| 2917 | 25 | 6.25 | 25 | 12.5 | 50 | 25 | 25 | 12.5 | 3.13 | 1.56 | 3.13 | 1.56 |
| 2918 | 50 | 6.25 | 25 | 6.25 | 200 | 12.5 | 25 | 6.25 | 1.56 | 0.78 | 1.56 | 0.78 |
| 2919 | 50 | 25 | 50 | 12.5 | 100 | 100 | 100 | 25 | 6.25 | 3.13 | 3.13 | 1.56 |
| 3002 | 12.5 | 6.25 | 12.5 | 3.13 | 6.25 | 1.56 | 3.13 | 1.56 | 3.13 | 1.56 | 3.13 | 0.78 |
Key: MH= Mueller-Hinton (MH) broth; MH+CCCP= MH broth containing 50 µg/ml carbonyl cyanide m-chlorophenyl hydrazone (CCCP); MH+BP= MH broth containing 30 µg/ml 2, 2′-bipyridyl; MH+BP/CCCP= MH broth containing 30 µg/ml 2,2’-bipyridyl and 50 µg/ml carbonyl cyanide m-chlorophenyl hydrazine. PA= P. aeruginosa PA01; EC= BW25113; ECΔtolC= E. coli BW25113 ΔtolC derivative JW5503-1.